Foresight Biotherapeutics
New York
About Foresight Biotherapeutics
Foresight Biotherapeutics is a clinical-stage drug development company pioneering novel therapies designed to address significant unmet needs in ophthalmology and otolaryngology. Foresight’s platform Povidone-Iodine (PVP-I) technology represents an important breakthrough in the treatment of ocular and otic inflammation including bacterial, viral and fungal infections. This platform enables PVP-I, a well-characterized broad spectrum antiseptic with no known microbial resistance, to be formulated in combination with a range of anti-inflammatory agents.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $17.0M
- Funding stage: M&A
- Last round: Series Unknown (Nov 2013)
- Website: foresightbio.com
- Phone: 646-747-9100
Industries & Categories
Biotechnology, Health Diagnostics, Therapeutics
Canonical: https://fsome.com/organization/foresight-biotherapeutics-2863947 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.